Browse Newsroom

InsuLife receives Commercialisation Grant from Innovation Norway

June 21, 2020

We are excited to announce that Innovation Norway has approved our application for Commercialisation grant of NOK 750,000, for initial activities to build understanding of the clinical development path requirements of INS-2301 (formerly named Levellor) with the European Medicines Agency, and compile application for an initial clinical pilot study to be undertaken in Norway. We are excited to collaborate with Innovation Norway on these activities and also further future projects.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved